Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors

Pembrolizumab, a potent antibody against programmed death 1 (PD‐1) receptor, has shown robust antitumor activity and manageable safety in patients with advanced solid tumors. Its pharmacokinetic (PK) properties were analyzed with population PK modeling using pooled data from the KEYNOTE‐001, −002, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahamadi, M, Freshwater, T, Prohn, M, Li, CH, de Alwis, DP, de Greef, R, Elassaiss‐Schaap, J, Kondic, A, Stone, JA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270291/
https://www.ncbi.nlm.nih.gov/pubmed/27863186
http://dx.doi.org/10.1002/psp4.12139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270291/
https://www.ncbi.nlm.nih.gov/pubmed/27863186
http://dx.doi.org/10.1002/psp4.12139

Ejemplares similares